BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dos Santos EUD, Sampaio TF, Tenório Dos Santos AD, Bezerra Leite FC, da Silva RC, Crovella S, Asano AGC, Asano NMJ, de Souza PRE. The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson's disease. J Pharm Pharmacol 2019;71:206-12. [PMID: 30353564 DOI: 10.1111/jphp.13031] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Soraya GV, Ulhaq ZS, Shodry S, A'raaf Sirojan Kusuma M, Herawangsa S, Sativa MO, Gustaf A, Faridwazdi DAN, Florentia SW, Raisa N, Bintang AK, Akbar M. Polymorphisms of the dopamine metabolic and signaling pathways are associated with susceptibility to motor levodopa-induced complications (MLIC) in Parkinson's disease: a systematic review and meta-analysis. Neurol Sci 2022;43:3649-70. [PMID: 35079903 DOI: 10.1007/s10072-021-05829-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Dogra N, Nagpal D, Aeri V, Ahmad S, Pande Katare D. Evaluating the synergistic effect of Mucuna prurines extract and sesame oil against the Parkinson’s disease zebrafish model: in-vivo / in-silico approach. All Life 2021;14:1022-42. [DOI: 10.1080/26895293.2021.1994472] [Reference Citation Analysis]
3 Vuletić V, Rački V, Papić E, Peterlin B. A Systematic Review of Parkinson's Disease Pharmacogenomics: Is There Time for Translation into the Clinics? Int J Mol Sci 2021;22:7213. [PMID: 34281267 DOI: 10.3390/ijms22137213] [Reference Citation Analysis]
4 Cacabelos R, Carrera I, Martínez O, Alejo R, Fernández-Novoa L, Cacabelos P, Corzo L, Rodríguez S, Alcaraz M, Nebril L, Tellado I, Cacabelos N, Pego R, Naidoo V, Carril JC. Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmacogenomics. Med Res Rev 2021;41:2841-86. [PMID: 34106485 DOI: 10.1002/med.21838] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Magistrelli L, Ferrari M, Furgiuele A, Milner AV, Contaldi E, Comi C, Cosentino M, Marino F. Polymorphisms of Dopamine Receptor Genes and Parkinson's Disease: Clinical Relevance and Future Perspectives. Int J Mol Sci 2021;22:3781. [PMID: 33917417 DOI: 10.3390/ijms22073781] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
6 Cacabelos R, Carrera I, Martínez O, Naidoo V, Cacabelos N, Aliev G, Carril JC. Influence of dopamine, noradrenaline, and serotonin transporters on the pharmacogenetics of Atremorine in Parkinson's disease. Drug Dev Res 2021;82:695-706. [PMID: 33458869 DOI: 10.1002/ddr.21784] [Reference Citation Analysis]
7 Zhao L, Yu C, Lv J, Cui Y, Wang Y, Hou C, Yu J, Guo B, Liu H, Li L. Fluoride exposure, dopamine relative gene polymorphism and intelligence: A cross-sectional study in China. Ecotoxicol Environ Saf 2021;209:111826. [PMID: 33360592 DOI: 10.1016/j.ecoenv.2020.111826] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
8 Dos Santos EUD, da Silva IIFG, Asano AGC, Asano NMJ, De Mascena Diniz Maia M, de Souza PRE. Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study. Mol Biol Rep 2020;47:8997-9004. [PMID: 33151475 DOI: 10.1007/s11033-020-05956-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Song N, Du J, Gao Y, Yang S. Epitranscriptome of the ventral tegmental area in a deep brain-stimulated chronic unpredictable mild stress mouse model. Transl Neurosci 2020;11:402-18. [PMID: 33343932 DOI: 10.1515/tnsci-2020-0146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Cerri S, Mus L, Blandini F. Parkinson's Disease in Women and Men: What's the Difference? J Parkinsons Dis 2019;9:501-15. [PMID: 31282427 DOI: 10.3233/JPD-191683] [Cited by in Crossref: 53] [Cited by in F6Publishing: 102] [Article Influence: 26.5] [Reference Citation Analysis]
11 Cacabelos R. Pharmacogenomics of drugs used to treat brain disorders. Expert Review of Precision Medicine and Drug Development 2020;5:181-234. [DOI: 10.1080/23808993.2020.1738217] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
12 Dos Santos EUD, Duarte EBC, Miranda LMR, Asano AGC, Asano NMJ, Maia MMD, de Souza PRE. Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinson's Disease. Neuromolecular Med 2019;21:295-302. [PMID: 31119645 DOI: 10.1007/s12017-019-08549-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Damasceno Dos Santos EU, Duarte EBC, Miranda LMR, Asano AGC, Asano NMJ, Maia MMD, de Souza PRE. Pharmacogenetic Profile and the Occurrence of Visual Hallucinations in Patients With Sporadic Parkinson's Disease. J Clin Pharmacol 2019;59:1006-13. [PMID: 30794329 DOI: 10.1002/jcph.1394] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]